Sildenafil Citrate Tablet, Film Coated
Product Images NDC 72888-018

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Sildenafil Citrate (NDC 72888-018). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Advagen Pharma Ltd, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Principal Display Panel (20 mg Tablet Bottle Label)

Label for Sildenafil Tablets USP 20 mg, film-coated oral tablets distributed by Advagen Pharma Limited and manufactured by Rubicon Research Private Limited. The label includes storage instructions, dosage form, NDC 72888-018-00, packaging quantity of 1,000 tablets, and contains a pharmacist dispensing notice. The label also shows barcodes and manufacturer address information.*

FDA Label Image

Principal Display Panel (20 mg Tablet Bottle Label)

Sildenafil Tablets USP 20 mg film-coated tablet label showing the NDC 72888-018. The label includes dosage details, storage instructions, distributor Advagen Pharma Limited, and manufacturer Rubicon Research Private Limited. The package contains 90 tablets and includes a pharmacist instruction to dispense with the patient information sheet.*

FDA Label Image

Graph (Sildenafil Tablets Usp 20mg Figure 06)

A line graph showing estimated cumulative mortality rate (%) over time in years. It compares three groups labeled High Dose, Medium Dose, and Low Dose with corresponding stepwise lines. The High Dose group has the highest cumulative mortality rate after five years, followed by Medium Dose, and Low Dose showing the lowest. The number at risk is listed above the graph for each group at various time points.*

FDA Label Image

Graph (Sildenafil Tablets Usp 20mg Figure 07)

A chart showing the fold change and 90% confidence intervals for pharmacokinetic parameters AUC and Cmax of sildenafil when coadministered with various interacting drugs. It includes drugs like Atorvastatin, Azithromycin, Bosentan, Cimetidine, Erythromycin, Maalox, Oral Contraceptives, Ritonavir, and Saquinavir, with recommendations on dose adjustment ranging from no dose adjustment to coadministration not recommended.*

FDA Label Image

Graph (Sildenafil Tablets Usp 20mg Figure 08)

A chart presenting fold change and 90% confidence intervals of pharmacokinetic parameters (AUC, Cmax, INR, BT) of sildenafil when coadministered with various interacting drugs such as Acenocoumarol, Aspirin, Atorvastatin, Bosentan, multiple doses of Doxazosin, Ethinyloestradiol, Levonorgestrel, Phenprocoumon, Ritonavir, Saquinavir, and Tolbutamide. Recommendations on dose adjustments or coadministration caution are included alongside each drug.*

FDA Label Image

Graph (Sildenafil Tablets Usp 20mg Figure 09)

A line graph depicting changes from baseline in meters over a 12-week study. The x-axis shows study weeks (4, 8, 12) and the y-axis shows change from baseline. Data points with error bars represent four groups: Placebo (circle), Sildenafil 20mg TID (square), Sildenafil 40mg TID (diamond), and Sildenafil 80mg TID (triangle). The graph shows trends for each treatment group over time.*

FDA Label Image

Graph (Sildenafil Tablets Usp 20mg Figure 10)

A forest plot showing placebo-corrected change in 6-minute walk distance (meters) for Sildenafil 20 mg TID compared to placebo across various subgroups including baseline walk distance, etiology, PH criteria for functional capacity and therapeutic class, gender, age, mean PAP, and PVRI.*

FDA Label Image

Graph (Sildenafil Tablets Usp 20mg Figure 11)

A Kaplan-Meier curve comparing the percentage without a clinically worsening event over 112 days from randomization between two groups: Placebo (solid line) and Sildenafil (dashed line). The y-axis shows the percentage without worsening, and the x-axis shows days from randomization, illustrating higher event-free survival in the Sildenafil group versus placebo over time.*

FDA Label Image

Graph (Sildenafil Tablets Usp 20mg Figure 12)

A line graph depicting the mean change from baseline in meters over a 12-week study period for Sildenafil at doses of 1 mg TID, 5 mg TID, and 20 mg TID. The y-axis shows change from baseline in meters, while the x-axis represents weeks 4, 8, and 12. Error bars indicate standard error for each treatment at each time point.*

FDA Label Image

Structure Formula (Sildenafil Tablets Usp 20mg Structure)

Chemical structure diagram of sildenafil, the active ingredient in Sildenafil Citrate tablets. The diagram depicts the molecular arrangement with labeled functional groups consistent with the chemical makeup of sildenafil.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.